免疫疗法
溶瘤病毒
医学
癌症免疫疗法
免疫系统
嵌合抗原受体
食品药品监督管理局
癌症
不利影响
免疫学
药理学
内科学
作者
Ziqin Chen,Tiantian Hu,Jing Zhou,Xiaolei Gu,Song Chen,Qing Qi,Ling Wang
出处
期刊:Life Sciences
[Elsevier BV]
日期:2024-01-21
卷期号:340: 122419-122419
被引量:3
标识
DOI:10.1016/j.lfs.2024.122419
摘要
Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency. We also review the latest progress in immune drugs approved by the National Medical Products Administration, including monoclonal antibodies, cytokines, OVs, and chimeric antigen receptor-T cell therapy, to help understand the clinical application of tumor immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI